Although endocrine therapy, including estrogen suppression and direct ER targeting, is widely applied in the treatment of ER+ breast cancer, acquired resistance often occurs and remains a major challenge for the treatment of ER+ patients [3]; thus, novel targets and effective therapeutic strategies for breast cancer patients are urgently needed. The gene discussed is ESR1; the disease is breast cancer.